Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Miglustat

11 evidence topics · 12 sources

Approval for Niemann-Pick disease type C outside the United States and off-label use in the United States
Randomized controlled trial in participants aged 12 years or older and an uncontrolled pediatric cohort

“Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients aged 12 years or older who had NPC (n=29) were randomly assigned to receive either miglustat 200 mg three times a day (n=20) or standard care (n=9) for 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“12 children younger than 12 years of age were included in an additional cohort; all received miglustat at a dose adjusted for body surface area.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The primary endpoint was horizontal saccadic eye movement (HSEM) velocity, based on its correlation with disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At 12 months, HSEM velocity had improved in patients treated with miglustat versus those receiving standard care; results were significant when patients taking benzodiazepines were excluded (p=0.028).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Children showed an improvement in HSEM velocity of similar size at 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Improvement in swallowing capacity, stable auditory acuity, and a slower deterioration in ambulatory index were also seen in treated patients older than 12 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The safety and tolerability of miglustat 200 mg three times a day in study participants was consistent with previous trials in type I Gaucher disease, where half this dose was used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Survival with and without miglustat: pooled national cohorts and the NPC Registry

“Overall, 384 (57.4%) patients in the Neurological onset group and 329 (55.8%) in the Diagnosis group were treated with miglustat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Miglustat treatment was associated with a significant reduction in the risk of mortality in neurological onset group patients (adjusted HR [95% CI] 0.510 [0.335, 0.777]; P < .01) (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The effect was consistent across all four age‐at‐neurological‐onset sub‐groups, with a trend that favoured miglustat treatment; all HRs were between 0.364 (late infantile patients) and 0.671 (early infantile patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Results were statistically significant for late infantile patients (HR [95% CI] 0.364 [0.165, 0.801]; P < .05); statistical significance was not achieved in the remaining age‐at‐neurological‐onset sub‐groups (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Miglustat treatment was associated with a significant reduction in the risk of mortality in diagnosis group patients (HR [95% CI] 0.441 [0.293, 0.664]; P < .001) (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In conclusion, this study is the first exploratory analysis conducted in the largest pool of observational data for patients with NP‐C to date, treated in a real‐world setting and with a broad geographical representation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Swallowing outcomes in a single-center cohort with neurological onset before age 15 years

“Miglustat, a drug used off-label in the United States for the treatment of NPC1, appears to stabilize neurologic disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In this cohort study of 50 individuals with Niemann-Pick disease, type C1 with neurologic disease onset before age 15 years, miglustat use was associated with stabilized swallowing function and reduced aspiration risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Miglustat use was associated with decreased odds of worse American Speech-Language-Hearing Association National Outcome Measurement System swallowing domain outcomes in all 3 subsets (overall: odds ratio [OR], 0.09 [95% CI, 0.02-0.36); P < .001; early childhood: OR, 0.17 [95% CI, 0.04-0.67]; P = .01; late childhood: OR, 0.05 [95% CI, 0.01-0.29]; P = .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Miglustat use was associated with decreased odds of worse Rosenbek aspiration-penetration scale outcomes in the overall cohort (OR, 0.28 [95% CI, 0.08-0.95]; P = .04) but not in each subgroup (early childhood: OR, 0.27 [95% CI, 0.06-1.22]; P = .09; late childhood: OR, 0.38 [95% CI, 0.06-2.33]; P = .29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Infantile onset: French pediatric cohort treated in clinical practice
Early infantile onset: French retrospective comparison of treated and untreated patients